Cancer Research CTRC-AACR San Antonio Breast Cancer Symposium  09 AM Call for Abstracts
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 38, 3150-3153, October 1, 1978]
© 1978 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Papac, R.
Right arrow Articles by Capizzi, R. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Papac, R.
Right arrow Articles by Capizzi, R. L.

Controlled Trial of Methotrexate and Bacillus Calmette-Guérin Therapy for Advanced Head and Neck Cancer1

Rose Papac, David R. Minor2,3, Seth Rudnick2,4, Lawrence R. Solomon and Robert L. Capizzi4

Veterans Administration Hospital, West Haven, Connecticut 06516 [R. P., L. R. S.], and Yale University School of Medicine, New Haven, Conne ticut 06510 [R. P., D. R. M., S. R., L. R. S., R. L. C.]

Thirty-eight patients with advanced, inoperable squamous cell carcinoma of the head and neck were randomized to receive methotrexate alone or methotrexate with Bacillus Calmette-Guérin. The response rates with methotrexate (3 of 19) and methotrexate plus B. Calmette-Guérin (4 of 16) were similar, as was the duration of response and survival of the two groups. The results of in vitro immunological studies of lymphocytes were assessed. Marked weight loss, poor performance status, and distant metastases were the most important prognostic factors. The presence of anergy was significantly correlated with weight loss. This study also indicated that a large tumor burden is a frequent occurrence in advanced head and neck cancer and may account for the lack of efficacy of B. Calmette-Guérin.

1 This work was supported in part by National Cancer Institute Grants 54583 and CA-09200 and by the Veterans Administration.

2 Postdoctoral Fellow in Oncology.

3 Present address: Saint Francis Hospital, 900 Hyde St., San Francisco, Calif. 94109.

4 Present address: University of North Carolina, Chapel Hill, N. C. 27514.

Received 5/10/78. Accepted 6/27/78.




This article has been cited by other articles:


Home page
J. Dent. Res.Home page
S. Xi and J.R. Grandis
Gene Therapy for the Treatment of Oral Squamous Cell Carcinoma
J. Dent. Res., January 1, 2003; 82(1): 11 - 16.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1978 by the American Association for Cancer Research.